Abstract
Immune checkpoint-blocking therapies have yielded positive clinical data in a series of human malignancies. Recent work from Le and colleagues strongly supports the use of these therapies for mismatch repair-deficient tumors, independent of underlying tumor type. These data suggest the importance of sensing the consequences of DNA damage in cancer immunotherapy.
Copyright © 2015 Elsevier Inc. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibodies, Monoclonal / pharmacology
-
Antibodies, Monoclonal / therapeutic use*
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
DNA Mismatch Repair
-
Humans
-
Neoplasms / drug therapy*
-
Neoplasms / metabolism
-
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
-
Tumor Microenvironment / drug effects
Substances
-
Antibodies, Monoclonal
-
Antineoplastic Agents
-
PDCD1 protein, human
-
Programmed Cell Death 1 Receptor